ClinicalTrials.Veeva

Menu

Serum 25-Hydroxyvitamin D and Neurological Disability in Multiple Sclerosis (EDSS)

U

University of Zintan

Status

Completed

Conditions

Multiple Sclerosis

Study type

Observational

Funder types

Other

Identifiers

NCT07123337
ZFM/2023/MS-01

Details and patient eligibility

About

Vitamin D is hypothesized to play a role in the immunopathology and progression of multiple sclerosis (MS), yet its association with neurological disability remains uncertain, particularly in North African populations.We conducted a cross-sectional study involving 369 adult MS patients across two tertiary neurology centers in Western Libya. Serum 25-hydroxyvitamin D [25(OH)D] levels and Expanded Disability Status Scale (EDSS) scores were collected. Pearson correlation, ANOVA, and multivariable linear regression were used to assess associations between vitamin D and disability, adjusting for age, BMI, disease duration, and physical activity. Missing data and outliers were handled systematically using validated R and Python workflows.

Enrollment

369 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Libyan nationals.
  • aged 18 years or older.
  • diagnosis of MS based on the 2017 revised McDonald criteria.
  • capable of providing informed consent.
  • had complete clinical, demographic, and biochemical data.

Exclusion criteria

  • presence of other neurological disorders that could mimic MS (e.g., neuromyelitis optica spectrum disorder or Lyme disease).
  • missing or incomplete medical records.
  • pregnancy or lactation.
  • extreme psychiatric or cognitive impairment.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems